The administration of pyridoxine-alpha-ketoglutarate (PAK) to type I and II diabetics previously treated with insulin and phenformin, reduces blood glucose, HbA1, and blood levels of lactate and pyruvate. The results of this double-blind clinical trial showed that PAK is advantageous for improving certain metabolic aspects in diabetics.
|Number of pages||5|
|Journal||International Journal of Clinical Pharmacology Therapy and Toxicology|
|Publication status||Published - 1983|
ASJC Scopus subject areas
- Pharmacology (medical)